A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE)

[1]  Y. Bang,et al.  Cox proportional hazard analysis of sunitinib (SU) efficacy across subgroups of patients (pts) with progressive pancreatic neuroendocrine tumors (NET). , 2010 .

[2]  H. Lane,et al.  Everolimus and PTK/ZK show synergistic growth inhibition in the orthotopic BL16/BL6 murine melanoma model , 2010, Cancer Chemotherapy and Pharmacology.

[3]  H. Hurwitz,et al.  Bevacizumab (B) plus everolimus (E) and panitumumab (P) in refractory advanced solid tumors. , 2016, Journal of Clinical Oncology.

[4]  H. Hurwitz,et al.  Bevacizumab (B) plus everolimus (E) in refractory metastatic colorectal cancer (mCRC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  C. Sternberg,et al.  A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Funda Meric-Bernstam,et al.  Targeting the mTOR signaling network for cancer therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  S. Flechner.  Reviewing the evidence for de novo immunosuppression with sirolimus. , 2008, Transplantation proceedings.

[8]  K. Hess,et al.  Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  S. Grant.  Cotargeting survival signaling pathways in cancer. , 2008, The Journal of clinical investigation.

[10]  R. Motzer,et al.  Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2008, The Lancet.

[11]  J. Soria,et al.  A phase 1/2 study investigating the combination of RAD001 (R) (everolimus) and erlotinib (E) as 2nd and 3rd line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (C): Phase 1 results , 2008 .

[12]  G. Tortora,et al.  EGFR antagonists in cancer treatment. , 2008, The New England journal of medicine.

[13]  G. Tortora,et al.  Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs , 2008, British Journal of Cancer.

[14]  Bohuslav Melichar,et al.  Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial , 2007, The Lancet.

[15]  H. Lenz,et al.  Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Gonen,et al.  Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Kris,et al.  Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall‐cell lung cancer , 2007, Cancer.

[18]  Dai Fukumura,et al.  Tumor microenvironment abnormalities: Causes, consequences, and strategies to normalize , 2007, Journal of cellular biochemistry.

[19]  J. Blay,et al.  Survival results with AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas: Update of phase II trial , 2007 .

[20]  Susan M. Chang,et al.  Phase I study of erlotinib and CCI-779 (temsirolimus) for patients with recurrent malignant gliomas (MG) (NABTC 04–02) , 2007 .

[21]  M. Hidalgo,et al.  Differential Metabolism of Gefitinib and Erlotinib by Human Cytochrome P450 Enzymes , 2007, Clinical Cancer Research.

[22]  David McDermott,et al.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.

[23]  P. Catalano,et al.  Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  R. Herbst,et al.  Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade , 2007, Molecular Cancer Therapeutics.

[25]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[26]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[27]  A. Bikfalvi,et al.  Tumor angiogenesis , 2020, Advances in cancer research.

[28]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[29]  Siobhan McCormack,et al.  Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non–small-cell lung, pancreatic, colon, and breast tumors , 2006, Molecular Cancer Therapeutics.

[30]  J. Haley,et al.  Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity , 2006, Molecular Cancer Therapeutics.

[31]  G. Clark,et al.  Effects of Smoking on the Pharmacokinetics of Erlotinib , 2006, Clinical Cancer Research.

[32]  G. Pond,et al.  Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer , 2006, British Journal of Cancer.

[33]  C. Prakash,et al.  METABOLISM AND EXCRETION OF ERLOTINIB, A SMALL MOLECULE INHIBITOR OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE, IN HEALTHY MALE VOLUNTEERS , 2006, Drug Metabolism and Disposition.

[34]  J. Hainsworth,et al.  Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Xin Li,et al.  TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  G. Demetri,et al.  Early response evaluation of therapy with AP23573 (an mTOR inhibitor) in sarcoma using [18F]2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) scan , 2005 .

[37]  G. Pond,et al.  A phase II trial of temsirolimus in metastatic neuroendocrine carcinomas (NECs) , 2005 .

[38]  L. Ellis,et al.  Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  R. McLendon,et al.  Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. , 2005, Molecular cancer therapeutics.

[40]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[41]  G. Tortora,et al.  Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. , 2003, European journal of cancer.

[42]  Christine C. Hudson,et al.  Regulation of Hypoxia-Inducible Factor 1α Expression and Function by the Mammalian Target of Rapamycin , 2002, Molecular and Cellular Biology.

[43]  J. Kovarik,et al.  Pharmacokinetic and Pharmacodynamic Assessments of HMG‐CoA Reductase Inhibitors When Coadministered with Everolimus , 2002, Journal of clinical pharmacology.

[44]  F. Tse,et al.  High-throughput semi-automated 96-well liquid/liquid extraction and liquid chromatography/mass spectrometric analysis of everolimus (RAD 001) and cyclosporin a (CsA) in whole blood. , 2001, Rapid communications in mass spectrometry : RCM.

[45]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[46]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[47]  R Simon,et al.  Accelerated titration designs for phase I clinical trials in oncology. , 1997, Journal of the National Cancer Institute.

[48]  HighWire Press,et al.  Drug metabolism and disposition : the biological fate of chemicals. , 1973 .